Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome

Abstract

Prasugrel plus aspirin achieved greater acute phase reduction of IST than clopidogrel plus aspirin, which might underlie the clinical benefit of potent antiplatelet therapy in ACS. (UMIN000018751).

Impact of the Antithrombotic Effects of Prasugrel on Mid-Term Vascular Healing in Acute Coronary Syndrome vs. Stable Coronary Artery Disease

“…21 According to previous studies, the amount of protruding tissue, including a thrombus, in the stented segment in acute-phase OCT images was smaller in patients with ACS receiving prasugrel than in those receiving clopidogrel. 3,4 This implies that the rapid and potent antithrombotic effect of prasugrel may reduce thrombotic burden even in the acute phase. It can be hypothesized that this acute antithrombotic effect would contribute to the prevalence of subclinical IST in the late phase, as a "legacy effect".…”